Orum Therapeutics Collaborates with Vertex Pharmaceuticals for the Development of Degrader-Antibody Conjugates
Shots:
- Orum & Vertex have entered into a global, multi-target license & option agreement under which Vertex will carry out research to discover novel targeted conditioning agents to be used with gene editing through Orum’s Dual-Precision Targeted Protein Degradation (TPD²) technology
- As per the agreement, Vertex gets the option to secure an exclusive global license to research, develop, manufacture & commercialize DACs after research for each target
- Orum is entitled to receive $15M upfront, an aggregate of $310M (per target for up to 3 targets) option payments & milestones plus tiered royalties
Ref: Vertex | Image: Vertex & Orum
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
